Developed Formulas
  • Supports treatment and prevention of cystitis

  • Counteracts pathogenic E. coli

  • Helps restore intestinal membrane integrity

  • Source of cranberry and D-mannose

Ready to market
Clinical test
In vitro test
Hydrosoluble powder
Allergen Free
Real time stability

Streptococcus thermophilus ST10 (DSM 25246)
Lactiplantibacillus plantarum LP01 (LMG P-21021)
Lacticaseibacillus paracaseiLPC09 (DSM 24243)
Cranberry (Vaccinium macrocarpon Aiton), fruit, d.j.
Proanthocyanidins (PACs)

Label Claim

Food supplement with probiotic strains.

Effective nutraceutical combination

EFSA Claim: contributes to the mantainance of normal mucosa

Scientific Rationale

Urinary tract infections (UTIs) remain among the most common bacterial infections, affecting approximately 150 million people worldwide each year [1,2]. They are caused by a variety of pathogens, primarily due to the ascent of intestinal bacteria, with uropathogenic E. coli (UPEC) being the predominant cause. Most UTIs are acute uncomplicated cystitis caused by E. coli (86%), though other microbes like Staphylococcus saprophyticus (4%), Klebsiella spp. (3%), Enterobacter spp. (1.4%), and Enterococcus spp. (0.5%) can also be involved [2,3]. UPEC accounts for about 80% of UTIs, typically triggering an inflammatory response and bacteriuria. The primary treatment for cystitis usually involves antibiotics; however, due to bacterial biofilm formation, antibiotic treatment often fails to completely eradicate the infection, leading to persistent bacteriuria and recurrences [4-8].

BIFICIST® is a food supplement combining specific probiotic strains, cranberry extract, and D-mannose, offering a dual and synergistic mechanism of action at both urinary and intestinal levels, enhancing the management of recurrent UTIs. The probiotic component of BIFICIST® includes Streptococcus thermophilus ST10, which synthesizes exopolysaccharides (EPS) in the gut lumen, Lactiplantibacillus plantarum LP01 and Lacticaseibacillus paracasei LPC09, known for their specific activities against E. coli [9] and other beneficial properties like anti-inflammatory activities [10] and protection/restoration of intestinal membrane integrity. Moreover, LPC09 is notably efficient in vitro at metabolizing oxalates, potentially offering protection from gut inflammation associated with prolonged supplementation with cranberry dry extract.

D-Mannose, a simple sugar closely related to glucose, is the primary bladder cell receptor site for uropathogenic E. coli [13]. It exerts its effects locally in the urinary bladder by binding to UPEC, which remains free in urine and is thus more easily eliminated during urination [14]. Scientific studies suggest that D-Mannose can be an effective aid in managing acute cystitis and as a prophylactic agent.

Cranberries, known for their antimicrobial activity against E. coli, create a natural physical-mechanical barrier against the adhesion of E. coli to the epithelial cells of the bladder and urinary tract, thus preventing UTI recurrence. BIFICIST® has been clinically studied in adult women with uncomplicated cystitis [19], showing significant improvement in symptoms like dysuria, frequent voiding, and urgency over 60 days of treatment (30 days of acute treatment with 2 sachets/day + 30 days of long-term treatment with 1 sachet/day). The study also recorded a low number of recurrences during the 1-month follow-up after treatment, suggesting a long-term barrier effect exerted by the product.


1. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis. 2001 Mar 1;183 Suppl 1:S1-4. doi: 10.1086/318850. 

2. Flores-Mireles AL, et al. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015 May;13(5):269-84. doi: 10.1038/nrmicro3432

3. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014 Mar;28(1):1-13. doi: 10.1016/j.idc.2013.09.003

4. Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician. 2011 Oct 1;84(7):771-6. 

5. Gupta K. et al. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA. 1999 Feb 24;281(8):736-8. doi: 10.1001/jama.281.8.736  

6. Ulett GC, et al. Uropathogenic Escherichia coli virulence and innate immune responses during urinary tract infection. Curr Opin Microbiol. 2013 Feb;16(1):100-7. doi: 10.1016/j.mib.2013.01.005

7. Gupta K. Emerging antibiotic resistance in urinary tract pathogens. Infect Dis Clin North Am. 2003 Jun;17(2):243-59. doi: 10.1016/s0891-5520(03)00006-0

8. Anderson GG, et al. Intracellular bacterial biofilm-like pods in urinary tract infections. Science. 2003 Jul 4;301(5629):105-7. doi: 10.1126/science.1084550

9. Mogna L, et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012 Oct;46 Suppl:S29-32. doi: 10.1097/MCG.0b013e31826852b7

10. Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019;  7:214. Doi: 10.35248/2329-8901.19.7.214.

11. Internal Probiotical’s data

12. Mogna L, et al. Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans? J Clin Gastroenterol. 2014 Nov-Dec;48 Suppl 1:S91-5.

13. Hung CS, et al. Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Mol Microbiol. 2002;44:903–915. Doi: 10.1046/j.1365-2958.2002.02915.x

14. Kranjčec B, et al. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014 Feb;32(1):79-84. Doi: 10.1007/s00345-013-1091-6

15. Hu X, et al. d-Mannose: Properties, Production, and Applications: An Overview. Compr Rev Food Sci Food Saf. 2016 Jul;15(4):773-785. doi:  10.1111/1541-4337.12211

16. Blumberg JB, et al. Cranberries and their bioactive constituents in human health. Adv Nutr. 2013 Nov 6;4(6):618-32. doi: 10.3945/an.113.004473

17. Howell AB. Cranberry proanthocyanidins and the maintenance of urinary tract health. Crit Rev Food Sci Nutr. 2002;42(3 Suppl):273-8. doi: 10.1080/10408390209351915

18. Sánchez Ballester F, et al.  Cysticlean® a highly pac standardized content in the prevention of recurrent urinary tract infections: an observational, prospective cohort study. BMC Urol. 2013 Jun 5;13:28. doi: 10.1186/1471-2490-13-28

19. Vicariotto F. Effectiveness of an association of a cranberry dry extract, D-mannose, and the two microorganisms Lactobacillus plantarum LP01 and Lactobacillus paracasei LPC09 in women affected by cystitis: a pilot study. J Clin Gastroenterol. 2014 Nov-Dec;48 Suppl 1:S96-101. doi: 10.1097/MCG.0000000000000224